A data analysis found the inhaled therapy Tyvaso outperformed a placebo at preserving lung function in people with IPF in a ...

United Therapeutics (NasdaqGS:UTHR) reported full Phase 3 TETON-2 trial data for nebulized Tyvaso in idiopathic pulmonary ...

Dr Nathan discusses the trajectory of IPF management. How do you envision these investigational agents potentially being implemented into future treatment paradigms for idiopathic pulmonary fibrosis ...

Steven Nathan, MD, discusses breakthrough treatments for idiopathic pulmonary fibrosis. There are several agents with new mechanisms of action in the pipeline for idiopathic pulmonary fibrosis (IPF).

Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with ...

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...

Add Yahoo as a preferred source to see more of our stories on Google. A 3D illustration of human lungs. The Food and Drug Administration on Tuesday approved a new drug for idiopathic pulmonary ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gersten: I've ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Prior to this trial, CS014 had positive outcomes in an ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks An announcement from PureTech Health ...

HealthDay News — Recommendations for idiopathic pulmonary fibrosis (IPF) treatment have been updated by an international group of respiratory societies. The updated clinical practice guideline was ...